Assessment of Economic Impact (PIES)
Streptococcus pneumoniae bacteria (pneumococcus) is a major cause of disease and disability worldwide, and is vaccine-preventable. In 2015, the Ministry of Health of Nepal began providing a 10-valent pneumococcal conjugate vaccine to infants (PCV10) as the vaccine was introduced into its routine infant immunization schedule.
Estimating the costs of pneumococcal disease and the potential for PCV to prevent these costs
Pneumococcal disease has significant economic costs to patients, families, governments, and society. Understanding the economic and financial burden of pneumococcal disease is critical to informing decisions about vaccine policy. However, few studies have evaluated the economic consequences of hospitalizations for pneumonia, meningitis, and sepsis in Nepal and South Asia.
When children are hospitalized, families may have to use savings, sell property, or take out loans in order to pay for their treatment. Additionally, their time spent away from work can have serious repercussions on household income. Out-of-pocket health spending has the potential to be catastrophic to households, and may push households into poverty.
Our team collected data from five hospitals in Nepal during 2016 to estimate the cost of hospitalized pneumonia, meningitis, and sepsis among children between one month and five years of age. We collected details on resources consumed to treat patients in the study hospitals. We also collected data on families’ out-of-pocket expenses from the time the patient showed symptoms to discharge from the study hospital, including direct medical costs, non-medical costs like food, transportation, and productivity losses. Long-term costs were not included. These data were used to estimate to costs of these illnesses to Nepali families, as well as to society more broadly, in 2018 US dollars.
Preliminary Results: a Significant Cost to Nepal
Fig. 1 Cost of a single episode of disease is significant
Despite variations at each hospital, episodes of pneumonia, meningitis, and sepsis represented a significant economic burden. The average cost per case, including productivity losses, was highest for meningitis (US$391), followed by sepsis (US$282), and pneumonia (US$188).
Meningitis and sepsis episodes were more expensive because of longer hospitalizations, more lab tests and procedures, and costlier medicines.
For every 100,000 children in Nepal between one month and 5 years, the cost of hospitalizing children for pneumococcal pneumonia was estimated to be $61,658 prior to the introduction of PCV10. Global burden of disease estimates models show that there were about 46,000 cases of pneumococcal pneumonia and 18,000 cases of severe pneumococcal pneumonia annually in Nepal in 2015.*
As the chart shows, the cost due to productivity loss was as important as the direct medical costs and presented a major proportion of the overall economic burden of these syndromes in Nepal.
Fig. 2 Losses in productivity are significant driver of total economic burden
Out of Pocket Spending
On average a case of pneumonia cost families $116. What does $116 mean for a typical Nepali family?
According to Nepali Bureau of Statistics, the average annual household consumption of Nepal in 2015/16 was Rs. 322,730 (about US$3,000). Broken down over a year, that’s US$250 per month:
- Half (53.8%) went to food.
- Rent accounted for 12.9%.
- The remaining spending went to durables (5.5%), education (4.0%), alcohol and tobacco (3.9%), utilities (2.2%) and other costs such as medical, social security, and cultural expenditure.
Catastrophic Spending Most Common with Poorest Families
The poorest households were most severely stressed when their children were hospitalized. In the poorest group of families, nearly 4 out of 10 pneumonia cases resulted in catastrophic expenditures for their households. In addition, nearly 60% of the poorest families that had children hospitalized for pneumonia reported using loans to finance hospitalization expenses.
What is Catastrophic Health Spending?
Out-of-pocket health spending is traditionally considered catastrophic when it exceeds 40% of a household’s annual non-food routine spending, including rent, utilities, and other household goods. However, this definition does not capture the immediate impact on households and may underestimate the impact on the poorest households that lack savings and resources to cope.
To evaluate the choice of catastrophic definition, we also performed sensitivity analyses using monthly household spending and different thresholds for each household consumption quintile. These definitions pointed to significant financial stress from spending on pneumonia hospitalizations in nearly every economic bracket except the wealthiest quintile. In fact, out-of-pocket payments for pneumonia hospitalizations exceeded 40% of the monthly household spending for more than 70% of households in the three poorest quintiles, indicating the short-term impact may be significant for households with limited savings and few assets.
Fig. 3 The poorest households are most vulnerable to financial catastrophe caused by pneumonia hospitalization, but most families experience significant financial disruption
Fig. 4 The poorest households are most vulnerable to financial catastrophe caused by pneumonia hospitalization, but the traditional method under-estimates this vulnerability
Given these findings, PCV10 has the potential to significantly reduce families’ catastrophic health spending and risk of impoverishment from having children hospitalized.
Data from this analysis can be used in economic evaluations of PCV in Nepal and other South Asian countries.
Using the data from this study, we are now modeling how the introduction of the vaccine has helped alleviate the economic burden of pneumococcal disease on families.
These results are not yet published. For more information, contact Cristina Garcia at email@example.com.
- Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Wahl, PhD et al. The Lancet Global Health. Vol. 6, Issue 7, pe744-e757, July 01, 2018